Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. It is creating an improved model for successful rare disease drug development that increases efficiency and effectiveness by changing the way the process is organized and conducted. The Company believes that it can deliver significant value to its patients by building a diverse and high quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine. 

Employee Rating

3.3More
TypePublic
HQNovato, US
Founded2010
Size (employees)376 (est)
Websiteultragenyx.com
Ultragenyx Pharmaceutical was founded in 2010 and is headquartered in Novato, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Ultragenyx Pharmaceutical

Emil D. Kakkis

Emil D. Kakkis

Chief Executive Officer and President
Camille Bedrosian

Camille Bedrosian

Chief Medical Officer and Executive Vice President
Wladimir Hogenhuis

Wladimir Hogenhuis

COO
Dennis Huang

Dennis Huang

Chief Technical Operations Officer and Executive Vice President
Thomas Kassberg

Thomas Kassberg

Chief Business Officer and Executive Vice President
Karah Parschauer

Karah Parschauer

General Counsel and Executive Vice President
Show more

Ultragenyx Pharmaceutical Office Locations

Ultragenyx Pharmaceutical has an office in Novato
Novato, (HQ)
60 Leveroni Ct
Show all (1)
Report incorrect company information

Ultragenyx Pharmaceutical Financials and Metrics

Ultragenyx Pharmaceutical Revenue

Ultragenyx Pharmaceutical's revenue was reported to be $2.61 m in FY, 2017
USD

Revenue (Q3, 2018)

11.8m

Gross profit (Q3, 2018)

11.5m

Gross profit margin (Q3, 2018), %

97.7%

Net income (Q3, 2018)

(87.3m)

EBIT (Q3, 2018)

(89.6m)

Market capitalization (4-Dec-2018)

2.6b

Closing stock price (4-Dec-2018)

50.4

Cash (30-Sep-2018)

83.0m
Ultragenyx Pharmaceutical's current market capitalization is $2.6 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

133.0k2.6m

Cost of goods sold

1.0k

Gross profit

2.6m

Gross profit Margin, %

100%
Quarterly
USDQ1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

17.0k111.0k17.0k198.0k10.7m12.8m11.8m

Cost of goods sold

225.0k141.0k273.0k

Gross profit

10.5m12.7m11.5m

Gross profit Margin, %

98%99%98%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

24.3m93.6m161.1m100.5m

Accounts Receivable

5.2m

Inventories

5.9m13.1m20.1m757.0k

Current Assets

193.4m450.2m401.7m269.6m
Quarterly
USDQ1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

55.4m17.5m178.0m52.4m166.7m70.8m55.1m142.3m159.5m90.8m60.4m226.7m110.9m83.0m

Accounts Receivable

3.7m17.4m9.2m

Inventories

2.1m3.3m5.6m

Current Assets

169.6m158.2m350.5m336.5m460.7m430.2m411.1m416.8m444.7m419.8m390.9m581.6m604.7m567.5m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(59.8m)(145.6m)(245.9m)(302.1m)

Depreciation and Amortization

684.0k1.4m3.4m5.8mwdxefcqufszuzezftuxetqsqxt

Inventories

(4.1m)(7.1m)(7.1m)

Accounts Payable

3.2m(2.0m)2.5m3.5m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(21.4m)(51.2m)(39.2m)(52.8m)(109.7m)(64.9m)(68.3m)(141.2m)(220.4m)30.3m(22.5m)(109.8m)

Depreciation and Amortization

463.0k1.2m1.2m2.2m3.3m6.2m12.2m16.6m

Accounts Payable

3.5m3.6m4.2m5.8m4.8m4.4m6.0m2.8m6.6m3.0m6.4m3.9m(1.3m)1.4m(593.0k)

Cash From Operating Activities

(34.9m)(84.5m)(61.2m)(110.0m)(172.0m)(89.5m)(165.6m)(234.7m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Ultragenyx Pharmaceutical News and Updates

Report incorrect company information

Ultragenyx Pharmaceutical Blogs

Ultragenyx to Present at Jefferies Gene Therapy Summit

Ultragenyx to Present at Jefferies Gene Therapy Summit Content Import Wed, 09/26/2018 - 08:34 Ultragenyx to Present at Jefferies Gene Therapy Summit Sep 26, 2018 This release is a backfill from a News Wire General NOVATO, Calif., Sep…

Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer

Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer Content Import Mon, 09/17/2018 - 08:33 Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer Sep 17, 2018 This releas…

Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update

NOVATO, Calif , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended June 30, 2018 .

Ultragenyx to Host Conference Call for Second Quarter 2018 Financial Results and Corporate Update

NOVATO, Calif. , July 27, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Thursday, August 2, 2018 at 5pm ET to

Ultragenyx Announces First Patient Dosed in Phase 1/2 study of DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa); FDA Grants Fast Track Designation to Gene Therapy Program

NOVATO, Calif. , July 26, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the first patient has been dosed in the Phase 1/2 study of DTX401, an

Ultragenyx Pharmaceutical Company Life and Culture

Report incorrect company information

Ultragenyx Pharmaceutical Frequently Asked Questions

  • When was Ultragenyx Pharmaceutical founded?

    Ultragenyx Pharmaceutical was founded in 2010.

  • Who are Ultragenyx Pharmaceutical key executives?

    Ultragenyx Pharmaceutical's key executives are Emil D. Kakkis, Camille Bedrosian and Wladimir Hogenhuis.

  • How many employees does Ultragenyx Pharmaceutical have?

    Ultragenyx Pharmaceutical has 376 employees.

  • What is Ultragenyx Pharmaceutical revenue?

    Latest Ultragenyx Pharmaceutical annual revenue is $2.6 m.

  • What is Ultragenyx Pharmaceutical revenue per employee?

    Latest Ultragenyx Pharmaceutical revenue per employee is $6.9 k.

  • Who are Ultragenyx Pharmaceutical competitors?

    Competitors of Ultragenyx Pharmaceutical include Nightstar Therapeutics, Aevi Genomic Medicine and Illumina.

  • Where is Ultragenyx Pharmaceutical headquarters?

    Ultragenyx Pharmaceutical headquarters is located at 60 Leveroni Ct, Novato.

  • Where are Ultragenyx Pharmaceutical offices?

    Ultragenyx Pharmaceutical has an office in Novato.

  • How many offices does Ultragenyx Pharmaceutical have?

    Ultragenyx Pharmaceutical has 1 office.